WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999041413) PROSTATE CANCER DRUG SCREENING
Latest bibliographic data on file with the International Bureau   

IA Considered Withdrawn 1999-12-27 00:00:00.0


Pub. No.:    WO/1999/041413    International Application No.:    PCT/US1999/003117
Publication Date: 19.08.1999 International Filing Date: 11.02.1999
Chapter 2 Demand Filed:    13.09.1999    
IPC:
C12Q 1/68 (2006.01)
Applicants: CALYDON, INC. [US/US]; 1324 Chesapeake Terrace Sunnyvale, CA 94089 (US) (For All Designated States Except US).
HENDERSON, Daniel, R. [US/US]; (US) (For US Only).
LAMPARSKI, Henry, G. [US/US]; (US) (For US Only).
SCHUUR, Eric, R. [US/US]; (US) (For US Only).
YU, De, Chao [US/US]; (US) (For US Only)
Inventors: HENDERSON, Daniel, R.; (US).
LAMPARSKI, Henry, G.; (US).
SCHUUR, Eric, R.; (US).
YU, De, Chao; (US)
Agent: MONROY, Gladys, H.; Morrison & Foerster LLP 755 Page Mill Road Palo Alto, CA 94304-1018 (US)
Priority Data:
09/022,732 12.02.1998 US
Title (EN) PROSTATE CANCER DRUG SCREENING
(FR) CRIBLAGE DE MEDICAMENT POUR LE TRAITEMENT DU CANCER DE LA PROSTATE
Abstract: front page image
(EN)Screening of compounds for activity toward inhibition of prostate cancer cell proliferation is provided. A cell line is employed which can be used in conventional equipment for determining activity of compounds, where the cell line uses a marker whose expression is responsive to therapeutically active compounds.
(FR)L'invention concerne un criblage de composés visant à déceler l'activité qui tend à inhiber la prolifération des cellules cancéreuses dans le cancer de la prostate. On fait appel à une lignée cellulaire susceptible d'être utilisée avec un équipement classique pour déterminer l'activité des composés, ladite lignée ayant recours à un marqueur dont l'expression réagit à des composés thérapeutiquement actifs.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)